![Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-019-0611-6/MediaObjects/41416_2019_611_Fig1_HTML.png)
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
![Efficacy of cabazitaxel and the influence of clinical factors on the overall survival of patients with castration‐resistant prostate cancer: A local experience of a multicenter retrospective study - Takai - 2021 - Efficacy of cabazitaxel and the influence of clinical factors on the overall survival of patients with castration‐resistant prostate cancer: A local experience of a multicenter retrospective study - Takai - 2021 -](https://onlinelibrary.wiley.com/cms/asset/0eac280e-3782-4733-b173-c8cb30e88f5f/ajco13441-fig-0003-m.jpg)
Efficacy of cabazitaxel and the influence of clinical factors on the overall survival of patients with castration‐resistant prostate cancer: A local experience of a multicenter retrospective study - Takai - 2021 -
![Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel | Anticancer Research Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/40/1/335/F1.large.jpg)
Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel | Anticancer Research
![Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial - Annals of Oncology Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/80c8053f-136b-4bec-8c8f-417d0a19b38d/gr1.jpg)
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial - Annals of Oncology
![Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial - European Urology Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial - European Urology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/da552630-b915-469a-8695-738781f70eef/gr1.jpg)
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial - European Urology
![ASCO 2020: CARD: Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone ASCO 2020: CARD: Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone](https://www.urotoday.com/images/OS_CARD_trial.png)
ASCO 2020: CARD: Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone
![Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41416-019-0611-6/MediaObjects/41416_2019_611_Fig2_HTML.png)
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
Cabazitaxel shows a consistently greater survival benefit compared to mitoxantrone in patients with mCRPC | de Bono | Nowotwory. Journal of Oncology
![Kaplan-Meier estimates of the probability of overall survival (OS) and... | Download Scientific Diagram Kaplan-Meier estimates of the probability of overall survival (OS) and... | Download Scientific Diagram](https://www.researchgate.net/profile/Francois-Kleinclauss-2/publication/235383647/figure/fig1/AS:203204877918217@1425459226752/Kaplan-Meier-estimates-of-the-probability-of-overall-survival-OS-and-progression-free.png)
Kaplan-Meier estimates of the probability of overall survival (OS) and... | Download Scientific Diagram
![Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41416-019-0611-6/MediaObjects/41416_2019_611_Fig3_HTML.png)
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
![Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer | Anticancer Research Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/39/6/3089/F2.large.jpg)
Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer | Anticancer Research
![The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients | BMC Cancer | Full Text The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-019-5342-9/MediaObjects/12885_2019_5342_Fig2_HTML.png)
The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients | BMC Cancer | Full Text
![ASCO GU 2021: Cabazitaxel Multiple Rechallenge in Metastatic Castration-Resistant Prostate Cancer: A Therapeutic Option to Increase Overall Survival? ASCO GU 2021: Cabazitaxel Multiple Rechallenge in Metastatic Castration-Resistant Prostate Cancer: A Therapeutic Option to Increase Overall Survival?](https://www.urotoday.com/images/ASCOGU21_Cedric_Pobel_1.png)
ASCO GU 2021: Cabazitaxel Multiple Rechallenge in Metastatic Castration-Resistant Prostate Cancer: A Therapeutic Option to Increase Overall Survival?
![Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel | Anticancer Research Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/38/7/4179/F1.large.jpg)
Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel | Anticancer Research
![ASCO 2018: Cabazitaxel in mCRPC: Real-life Use, Effectiveness, Safety, and Quality of Life in the FUJI Cohort ASCO 2018: Cabazitaxel in mCRPC: Real-life Use, Effectiveness, Safety, and Quality of Life in the FUJI Cohort](https://www.urotoday.com/images/Cabazitaxel_mCRPC_OverallSurvival.png)